Common types of supraventricular tachycardia: Diagnosis and management

American Family Physician

Volumn 82, Issue 8, 2010, Pages 942-952

  Colucci, Randall A ^a   Silver, Mitchell J ^b   Shubrook, Jay ^a  

^a OHIO UNIVERSITY   (United States)

^b McConnell Heart Health Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE; AMIODARONE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIGOXIN; DILTIAZEM; DISOPYRAMIDE PHOSPHATE; ESMOLOL; FLECAINIDE ACETATE; METOPROLOL; PROCAINAMIDE; PROPAFENONE; QUINIDINE; VERAPAMIL; ANTIARRHYTHMIC AGENT;

ANAMNESIS; ARTICLE; ATRIOVENTRICULAR NODAL REENTRANT TACHYCARDIA; ATRIOVENTRICULAR RECIPROCATING TACHYCARDIA; CATHETER ABLATION; CONSTIPATION; CRYOTHERAPY; DIZZINESS; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUCED DISEASE; DRUG SAFETY; DYSPNEA; ELECTROCARDIOGRAPHY; FATIGUE; HEART ATRIOVENTRICULAR NODE; HEART ATRIUM FIBRILLATION; HEART AUTOMATICITY; HEART FAILURE; HEART HEMODYNAMICS; HEART PALPITATION; HEART RHYTHM; HEART VENTRICLE FIBRILLATION; HIS PURKINJE BLOCK; HUMAN; HYPOTENSION; INCIDENCE; LOADING DRUG DOSE; LONG TERM CARE; LUNG FIBROSIS; LUPUS VULGARIS; OPTIC NEURITIS; PATHOGENESIS; PHYSICAL EXAMINATION; QRS COMPLEX; QUALITY OF LIFE; RADIOFREQUENCY ABLATION; SUPRAVENTRICULAR TACHYCARDIA; SYMPTOM; THORAX PAIN; THYROID DISEASE; TREATMENT RESPONSE; URINE RETENTION; WOLFF PARKINSON WHITE SYNDROME; DIFFERENTIAL DIAGNOSIS; EARLY DIAGNOSIS; HEART RATE; PHYSIOLOGY; PROGNOSIS; REVIEW; UNITED STATES;

ANTI-ARRHYTHMIA AGENTS; CATHETER ABLATION; DIAGNOSIS, DIFFERENTIAL; EARLY DIAGNOSIS; ELECTROCARDIOGRAPHY, AMBULATORY; HEART RATE; HUMANS; INCIDENCE; PROGNOSIS; TACHYCARDIA, SUPRAVENTRICULAR; UNITED STATES;

EID: 78049524423     PISSN: 0002838X     EISSN: 0002838X     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Fuster V, Rydén LE, Cannom DS, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (writing committee to revise the 2001 guidelines for the management of patients with atrial fibrillation): developed in collaboration with the European Heart Rhythm Association and Heart Rhythm Society [published correction appears in Circulation. 2007;116(6):e138]. Circulation. 2006;114(7):e257-e354.
2. Blomström-Lundqvist C, Scheinman MM, Aliot EM, et al. ACC/AHA/ESC guidelines for the management of patients with supraventricular arrhythmias-executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (writing committee to develop guidelines for the management of patients with supraventricular arrhythmias) developed in collaboration with NASPE-Heart Rhythm Society. J Am Coll Cardiol. 2003;42(8):1493-1531.
3. Kumar UN, Rao RK, Scheinman MM. The 12-lead electrocardiogram in supraventricular tachycardia. Cardiol Clin. 2006;24(3):427-437, ix.
4. Porter MJ, Morton JB, Denman R, et al. Influence of age and gender on the mechanism of supraventricular tachycardia. Heart Rhythm. 2004;1(4):393-396.
5. Ko JK, Deal BJ, Strasburger JF, Benson DW Jr. Supraventricular tachycardia mechanisms and their age distribution in pediatric patients. Am J Cardiol. 1992;69(12):1028-1032.
6. Wellens HJ, Brugada P. Mechanisms of supraventricular tachycardia. Am J Cardiol. 1988;62(6):10D-15D.
7. Orejarena LA, Vidaillet H Jr, DeStefano F, et al. Paroxysmal supraventricular tachycardia in the general population. J Am Coll Cardiol. 1998;31(1):150-157.
8. Rodriguez LM, de Chillou C, Schläpfer J, et al. Age at onset and gender of patients with different types of supraventricular tachycardias. Am J Cardiol. 1992;70(13):1213-1215.
9. Akhtar M, Jazayeri MR, Sra J, Blanck Z, Deshpande S, Dhala A. Atrioventricular nodal reentry. Clinical, electrophysiological, and therapeutic considerations. Circulation. 1993;88(1):282-295.
10. Ganz LI, Friedman PL. Supraventricular tachycardia. N Engl J Med. 1995;332(3):162-173.
11. Chauhan VS, Krahn AD, Klein GJ, Skanes AC, Yee R. Supraventricular tachycardia. Med Clin North Am. 2001;85(2):193-223, ix.
12. Mark DG, Brady WJ, Pines JM. Preexcitation syndromes: diagnostic considerations in the ED. Am J Emerg Med. 2009;27(7):878-888.
13. Katoh T, Ohara T, Kim EM, Hayakawa H. Non-invasive diagnosis of concealed Wolff-Parkinson-White syndrome by detection of concealed anterograde pre-excitation. Jpn Circ J. 2001;65(5):367-370.
14. Roberts-Thomson KC, Kistler PM, Kalman JM. Focal atrial tachycardia II: management. Pacing Clin Electrophysiol. 2006;29(7):769-778.
15. Kistler PM, Roberts-Thomson KC, Haqqani HM, et al. P-wave morphology in focal atrial tachycardia: development of an algorithm to predict the anatomic site of origin. J Am Coll Cardiol. 2006;48(5):1010-1017.
16. Kastor JA. Multifocal atrial tachycardia. N Engl J Med. 1990;322(24):1713-1717.
17. Lessmeier TJ, Gamperling D, Johnson-Liddon V, et al. Unrecognized paroxysmal supraventricular tachycardia. Potential for misdiagnosis as panic disorder. Arch Intern Med. 1997;157(5):537-543.
18. Fenelon G, Wijns W, Andries E, Brugada P. Tachycardiomyopathy: mechanisms and clinical implications. Pacing Clin Electrophysiol. 1996;19(1):95-106.
19. Delacrétaz E. Clinical practice. Supraventricular tachycardia. N Engl J Med. 2006;354(10):1039-1051.
20. Smith G, Morgans A, Boyle M. Use of the Valsalva manoeuvre in the prehospital setting: a review of the literature. Emerg Med J. 2009;26(1):8-10.
21. Adlington H, Cumberbatch G. Carotid sinus massage: is it a safe way to terminate supraventricular tachycardia? Emerg Med J. 2009;26(6):459.
22. Libby P, ed. Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine. 8th ed. Philadelphia, Pa.: W.B. Saunders; 2007.
23. DiMarco JP, Miles W, Akhtar M, et al. Adenosine for paroxysmal supraventricular tachycardia: dose ranging and comparison with verapamil. Assessment in placebo-controlled, multicenter trials. The adenosine for PSVT study group [published correction appears in Ann Intern Med. 1990;113(12):996]. Ann Intern Med. 1990;113(2):104-110.
24. Belardinelli L, Linden J, Berne RM. The cardiac effects of adenosine. Prog Cardiovasc Dis. 1989;32(1):73-97.
25. Marine JE. Catheter ablation therapy for supraventricular arrhythmias. JAMA. 2007;298(23):2768-2778.
26. Glatter KA, Cheng J, Dorostkar P, et al. Electrophysiologic effects of adenosine in patients with supraventricular tachycardia. Circulation. 1999;99(8):1034-1040.
27. Fox DJ, Tischenko A, Krahn AD, et al. Supraventricular tachycardia: diagnosis and management. Mayo Clin Proc. 2008;83(12):1400-1411.
28. Klein GJ, Bashore TM, Sellers TD, Pritchett EL, Smith WM, Gallagher JJ. Ventricular fibrillation in the Wolff-Parkinson-White syndrome. N Engl J Med. 1979;301(20):1080-1085.
29. Anderson S, Blanski L, Byrd RC, et al. Comparison of the efficacy and safety of esmolol, a short-acting beta blocker, with placebo in the treatment of supraventricular tachyarrhythmias. The Esmolol vs Placebo Multicenter Study Group. Am Heart J. 1986;111(1):42-48.
30. Holdgate A, Foo A. Adenosine versus intravenous calcium channel antagonists for the treatment of supraventricular tachycardia in adults. Cochrane Database Syst Rev. 2006;(4):CD005154.
31. Pritchett EL, Wilkinson WE. Mortality in patients treated with flecainide and encainide for supraventricular arrhythmias. Am J Cardiol. 1991;67(11):976-980.
32. Reimold SC, Maisel WH, Antman EM. Propafenone for the treatment of supraventricular tachycardia and atrial fibrillation: a meta-analysis. Am J Cardiol. 1998;82(8A):66N-71N.
33. Brugada P, Brugada J, Mont L, Smeets J, Andries EW. A new approach to the differential diagnosis of a regular tachycardia with a wide QRS complex. Circulation. 1991;83(5):1649-1659.
34. Vereckei A, Duray G, Szénási G, Altemose GT, Miller JM. Application of a new algorithm in the differential diagnosis of wide QRS complex tachycardia. Eur Heart J. 2007;28(5):589-600.
35. Marill KA, Wolfram S, Desouza IS, et al. Adenosine for wide-complex tachycardia: efficacy and safety. Crit Care Med. 2009;37(9):2512-2518.
36. Alboni P, Tomasi C, Menozzi C, et al. Efficacy and safety of out-of-hospital self-administered single-dose oral drug treatment in the management of infrequent, well-tolerated paroxysmal supraventricular tachycardia. J Am Coll Cardiol. 2001;37(2):548-553.
37. Winniford MD, Fulton KL, Hillis LD. Long-term therapy of paroxysmal supraventricular tachycardia: a randomized, double-blind comparison of digoxin, propranolol and verapamil. Am J Cardiol. 1984;54(8):1138-1139.
38. Borggrefe M, Budde T, Podczeck A, Breithardt G. High frequency alternating current ablation of an accessory pathway in humans. J Am Coll Cardiol. 1987;10(3):576-582.
39. Kay GN, Epstein AE, Dailey SM, Plumb VJ. Role of radiofrequency ablation in the management of supraventricular arrhythmias: experience in 760 consecutive patients. J Cardiovasc Electrophysiol. 1993;4(4):371-389.
40. Mitrani RD, Klein LS, Hackett FK, Zipes DP, Miles WM. Radiofrequency ablation for atrioventricular node reentrant tachycardia: comparison between fast (anterior) and slow (posterior) pathway ablation. J Am Coll Cardiol. 1993;21(2):432-441.
41. Goldberg AS, Bathina MN, Mickelsen S, Nawman R, West G, Kusumoto FM. Long-term outcomes on quality-of-life and health care costs in patients with supraventricular tachycardia (radiofrequency catheter ablation versus medical therapy). Am J Cardiol. 2002;89(9):1120-1123.
42. Cheng CH, Sanders GD, Hlatky MA, et al. Cost-effectiveness of radiofrequency ablation for supraventricular tachycardia [pubished correction appears in Ann Intern Med. 2001;135(10):933]. Ann Intern Med. 2000;133(11):864-876.